Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA announces further positive phase III data for new insulin U300 compared with Lantus-Reuters


Tuesday, 3 Dec 2013 01:00am EST 

Sanofi SA:An improved version of Sanofi SA's diabetes drug Lantus, known as U300, is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed - Reuters.The long-acting insulin U300 requires less frequent or lower dosing than Lantus and offers a more consistent insulin release.Analysts expect Sanofi SA to seek regulatory approval for U300 in the United States and Europe in 2014 and for the drug to reach global sales of $872 million by 2017, according to forecasts compiled by Thomson Reuters Cortellis.The detailed Phase III results showed that U300 was better than Lantus at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin.U300 also lowered the incidence of hypoglycemic events at any time of the day across the six-month study period.U300 met its goal in three other Phase III clinical trials, showing similar blood sugar level control as Lantus in patients with type 2 diabetes not previously treated with insulin and uncontrolled on oral medication, as well as in patients with type 1 diabetes already treated with insulin. 

Company Quote

82.0
-0.26 -0.32%
30 Jan 2015